Reverse Split Spurs 49% Rally as Indaptus Advances Decoy20 Trial
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Indaptus Therapeutics Inc (NASDAQ: INDP) is a clinical-stage biotechnology company headquartered in New York, New York. Founded in 2021, Indaptus focuses on immunotherapy that utilizes attenuated, non-pathogenic gram-negative bacteria to engage both innate and adaptive immune pathways. Its lead candidate, Decoy20, aims to prime and activate immune cells to target tumors and viral infections.
Corporate Structure
Indaptus Therapeutics operates with a small team of 2–10 employees and maintains a public listing on the NASDAQ Capital Market under the ticker INDP. Key members of the executive leadership include:
- Jeffrey A. Meckler, Chief Executive Officer, who has over 30 years of financial and healthcare leadership experience across various organizations, including Pfizer, Intec Pharma, and Cocrystal Pharma.
- Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, who developed the core technology at Decoy Biosystems and has over 35 years of experience in oncology drug discovery.
- Walt A. Linscott, Chief Operating Officer, who brings more than three decades of business development, operational, and legal experience in the life sciences sector.
Immunotherapy by Alex Robertson
Recent Developments and News
On June 27, 2025, Indaptus completed a one-for-twenty-eight reverse stock split to comply with NASDAQ listing standards, reducing its outstanding shares from approximately 16 million to about 572,000. In the second quarter of 2025, the company secured $5.7 million in financing and dosed the first patient in a Phase 1b/2 combination trial of Decoy20 with BeOne Medicines’ PD-1 inhibitor, tislelizumab. In November 2025, Dr. Michael Newman presented at Hanson Wade’s Donor Selection & Cell Source Summit in San Diego and at CICON25 in Utrecht, sharing new pre-clinical data regarding NK cells, gamma-delta T cells, and M1 macrophages.
Financial and Strategic Aspects
As of December 24, 2025, INDP shares closed at $2.91, with a price increase of 49.23% on trading volume of 3,714,491 shares. The company’s market capitalization is approximately $3.42 million. Indaptus reported a net loss of $16.87 million (TTM) and held $5.83 million in cash and cash equivalents (MRQ), with a debt-to-equity ratio of 0.19%. Its patent portfolio includes 34 issued or granted patents related to Decoy20 technology. A summary of key metrics is shown below:
| Metric | Value |
|---|---|
| Share price (12/24/2025) | $2.91 (+49.23%) |
| Market cap | $3.42 M |
| Cash and equivalents (MRQ) | $5.83 M |
| Net loss (TTM) | $16.87 M |
| Debt/Equity (MRQ) | 0.19% |
Strategically, the company is advancing Decoy20 through clinical development while seeking collaboration opportunities to expand its pipeline and extend its cash runway.
Market Position and Industry Context
Indaptus operates in the immuno-oncology and anti-viral therapeutics sector, competing with both cell-based therapies and small-molecule immunomodulators. Its bacterial PAMP (pathogen-associated molecular pattern) platform distinguishes it from antigen-targeted treatments by aiming to elicit broad immune activation without continuous exposure. The company targets solid tumors, hematologic malignancies, and chronic viral diseases using a single therapeutic platform.
tl;dr
On December 24, 2025, INDP shares increased by 49.23% to $2.91 following elevated trading activity. The company completed a one-for-twenty-eight reverse stock split (effective June 27, 2025), raised $5.7 million in Q2 2025 financing, and initiated dosing in a Phase 1b/2 trial combining Decoy20 with tislelizumab. Clinical presentations in November 2025 provided pre-clinical data relevant to upcoming developments.